4-tert-Butyl-N-(2-diethylamino-ethyl)-benzamide | 793-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-tert-Butyl-N-(2-diethylamino-ethyl)-benzamide
• 英文别名: 4-tert-butyl-N-[2-(diethylamino)ethyl]benzamide
• CAS: 793-04-4
• 化学式: C₁₇H₂₈N₂O
• 分子量: 276.422
• InChiKey: NFYXTDINQZFOON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Polyamine-substituted ligands for use as contrast agents
  申请人：Wolf Markus

  公开号：US20070202047A1

  公开（公告）日：2007-08-30

  The present invention relates to a polyamine-substituted ligand for the preparation of a contrast agent derived from a chelating molecule selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylentriamine-pentaacetic acid (DTPA), wherein at least one of the carboxylic groups of the chelating molecule is reacted with an amine of formula HNR 1 R 2 to form an amide bond, wherein R 1 , R 2 are independently selected from the group consisting of H; (CH 2 ) n —NR 3 R 4 ; and R 5 ; R 3 , R 4 are independently selected from the group consisting of H; (CH 2 ) m —NR 6 R 7 ; and (CH 2 ) m-1 —CH 3 ; R 6 , R 7 are independently selected from the group consisting of H; and (CH 2 ) o-1 —CH 3 ; n, m, o are independently 2, 3, or 4; R 5 is of formula and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R 1 , R 2 is other than H. Furthermore, the invention relates to contrast agents for magnetic resonance imaging (MRI) comprising said ligands and in-vivo diagnostic methods based on MRI using said contrast agents.

  本发明涉及一种用于制备对比剂的聚胺取代配体，所述对比剂源自从1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸（DOTA）和二乙烯三胺五乙酸（DTPA）组成的羧基配体中选择的螯合分子，其中所述螯合分子的羧基之一与公式HNR1R2的胺反应形成酰胺键，其中R1、R2独立地选择自H；（CH2）n—NR3R4；和R5；R3、R4独立地选择自H；（ ）m—NR6R7；和（ ）m-1—CH3；R6、R7独立地选择自H；和（ ）o-1— ；n、m、o独立地为2、3或4；R5为公式，并且可选地，所述螯合分子的羧基之一进一步与具有1至18个碳原子的单烷基胺反应形成酰胺键；前提是R1、R2中至少一个不是H。此外，本发明涉及包括所述配体的磁共振成像（MRI）对比剂以及基于MRI使用所述对比剂的体内诊断方法。
• DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：Pierce C. Albert

  公开号：US20080014189A1

  公开（公告）日：2008-01-17

  The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及蛋白激酶抑制剂。该发明还提供了包含本发明化合物的药物组合物以及使用该组合物治疗各种疾病的方法。
• MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
  申请人：PARK John Edward

  公开号：US20100204211A1

  公开（公告）日：2010-08-12

  The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

  本发明涉及使用通式中6位取代的吲哚酮，其中R1至R5和X如权利要求1所定义，其异构体和盐，特别是其生理上可接受的盐，作为预防或治疗特定纤维化疾病的药物。
• INDAZOLYL TRIAZOL DERIVATIVES
  申请人：Jorand-Lebrun Catherine

  公开号：US20130274241A1

  公开（公告）日：2013-10-17

  Compounds of Formula (I) are used for the treatment of inflammation and autoimmune disorders.

  化合物（I）的公式被用于治疗炎症和自身免疫性疾病。
• MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20190038600A1

  公开（公告）日：2019-02-07

  The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.